Search results
Results From The WOW.Com Content Network
Lonza said on Tuesday it has capacity to fill syringes to serve makers of highly popular new weight-loss drugs in a class known as GLP-1, though it does not produce the active ingredient in those ...
lonza.com. Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development ...
Lonza said its medium-term strategy and outlook would be discussed in detail at its capital markets day on Oct. 17 and that Chairman Albert Baehny would take on the CEO responsibilities until the ...
The U.S. company had announced last week it was in talks with its partners that fill vials and syringes globally to downsize vaccine production. Moderna expects to absorb the demand currently ...
Revenue. US$750 million (2011) [2] Number of employees. 3,600 (2016) [1] Parent. Lonza Group. Website. capsugel.com. Capsugel is a company that manufactures and sells two-piece hard gelatin drug capsules. [3]: 703 Capsugel also sells equipment for filling empty and liquid capsules, as well as equipment for sealing liquid capsules.
Language links are at the top of the page across from the title.
Lonza Group has extended a collaboration with a major biopharmaceutical industry client for the supply of an antibody drug conjugate (ADC) against hard-to-treat cancers, the Swiss contract ...
Lonza Group Ag (LZAGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.